Home
Healthy and functional cells from discovery
to manufacturing
We enable transformative therapies with our patent-pending continuous Flowfect™ cell engineering platforms. The non-viral Flowfect™ technology is a fast, scalable, and gentle process that yields billions of high-quality engineered cells in minutes while maintaining cell health and function.

KYTOPEN enables cell engineering from discovery to manufacturing
Technology
We are transforming cell engineering
The Flowfect™ technology combines continuous fluid flow with electric fields for high efficiency delivery of payloads such as mRNA, DNA, and CRISPR Cas9 RNP to primary cells. By carefully synchronizing the pulse delivery with the fluid flow we have eliminated the harmful effects of traditional transfection via static electroporation. Our ex vivo cell engineering platform is compatible with primary cells being developed for immuno-oncology and gene editing applications.
PRESERVED VIABILITY & FUNCTIONALITY
Our platform allows you to safely engineer your cells with minimal impact to their overall health and function. High-quality engineered cell products upfront will ultimate translate into faster cell therapy access for patients.


AUTOMATED
HIGH
THROUGHPUT
DISCOVERY
We have fully automated cell engineering at the discovery scale. Whether you’re optimizing transfection conditions or discovering the next-generation cell therapy, Flowfect™ will accelerate your time to market.


KYTOPEN empowers your cells to flow from theory to therapy
Team
Meet the team












KYTOPEN enables safer and faster therapeutic development
Publications
The intersection of innovation and opportunity
Kytopen is an MIT spinout with multiple publications in high-impact scientific journals.

NATURE
SCIENTIFIC REPORTS

KYTOPEN helps you discover efficiently
Join Us
Be part of a dynamic team working at the intersection of engineering, biology, and
advanced cell manufacturing.
We have many open positions and look forward to receiving your application.
Contact
